Trying to keep up with the rules for peptides is a bit like trying to read a map while it is being rewritten. One minute a substance is everywhere, and the next, regulators are raising red flags.
Why are some peptides suddenly harder to find?
The FDA recently updated the status for several popular options. When a substance is placed in Category 2, it means the FDA has identified significant safety risks and it is no longer eligible for routine compounding—which is just the fancy word for when a specialized pharmacy makes a custom version of a drug for you.
As of March 2026, here is where things stand for some big names:
- BPC-157: This is currently listed as a Category 2 substance due to immunogenicity concerns (your body’s immune system potentially reacting to the drug) and a general lack of safety data. It is not FDA-approved.
- TB-500: The FDA cites a lack of human exposure data and similar immune system risks. It is also in Category 2 and not FDA-approved.
- CJC-1295 and Ipamorelin: These were moved to Category 2, with the FDA citing safety issues like an increased heart rate for CJC-1295.
- GHK-Cu: Even though you see it everywhere, it is not an FDA-approved injectable drug and carries immune system risks.
What about the peptides everyone is talking about?
While the ones above are facing hurdles, others have been through the ringer of clinical trials. Semaglutide and Tirzepatide have completed large Phase III studies (the final stage of testing before a drug hits the market).
- Semaglutide: In the STEP 1 study, participants saw 14.9% weight loss.
- Tirzepatide: In the SURMOUNT-1 study, it showed 22.5% weight loss and was found superior to semaglutide in a head-to-head trial.
Keeping an eye on safety signals
Even when a drug is approved, the FDA keeps a list of safety signals, which are basically reports of side effects that they want to monitor. For Semaglutide, common issues like nausea and vomiting are well-known and listed on the label. However, there are newer things to watch for:
- Delayed Gastric Emptying: This means food stays in your stomach longer, which can be a problem if you need surgery.
- NAION: This is a rare eye condition that is currently under review by regulators in Europe as of early 2025.
- Intestinal Obstruction: This was recently added to the label after reports of blockages in the gut.
Scientists are still working on these—turns out the human body is complicated. Who knew?
This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.